Uniqure B.V. News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.06.21	uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE) (GlobeNewswire)
16.06.21	uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
02.06.21	uniQure to Participate in Multiple Upcoming Industry Conferences in June (GlobeNewswire)
27.05.21	uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
13.05.21	uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector (GlobeNewswire)
10.05.21	uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
06.05.21	uniQure announces closing of commercialization and license agreement with CSL Behring (GlobeNewswire)
03.05.21	uniQure to Participate in Multiple Upcoming Industry Conferences in May (GlobeNewswire)
28.04.21	uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire)
26.04.21	uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program (GlobeNewswire)
08.04.21	uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain (GlobeNewswire)
05.04.21	uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
01.04.21	uniQure to Participate in Multiple Upcoming Industry Conferences in April (GlobeNewswire)
29.03.21	uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program (GlobeNewswire)
01.03.21	uniQure Announces 2020 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
26.02.21	uniQure to Participate in Multiple Upcoming Industry Conferences in March (GlobeNewswire)
09.02.21	ATHE Gets Funded For Parkinson's Research, No Safety Issues For QURE's Trial, TNXP On Watch (RTTNews)
08.02.21	uniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
01.02.21	uniQure to Participate in Multiple Upcoming Industry Conferences in February (GlobeNewswire)
22.12.20	NantKwest Stock Goes North, QURE's HOPE-B Trial On Hold, EU Greenlights First COVID-19 Vaccine (RTTNews)
21.12.20	uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program (GlobeNewswire)
08.12.20	uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematolo (GlobeNewswire)
07.12.20	uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B (GlobeNewswire)
02.12.20	uniQure to Participate in Multiple Upcoming Industry Conferences in December (GlobeNewswire)
30.11.20	uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
20.11.20	AZN's Covid Jab & Immunosenescence, PFE/BNTX To Seek Emergency Nod For Vaccine, QURE Aces HOPE-B (RTTNews)
19.11.20	uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B (GlobeNewswire)
04.11.20	uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
04.11.20	uniQure to Participate in Multiple Upcoming Industry Conferences in November (GlobeNewswire)
27.10.20	uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
13.10.20	uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
30.09.20	uniQure to Participate in Multiple Upcoming Industry Conferences in October (GlobeNewswire)
25.09.20	uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
03.09.20	uniQure to Participate in Multiple Upcoming Industry Conferences in September (GlobeNewswire)
26.08.20	uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development (GlobeNewswire)
30.07.20	uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
25.06.20	Stock Alert: UniQure Down 20% (RTTNews)
25.06.20	CSL Behring To Buy Late-Stage Gene Therapy Candidate For Hemophilia B Patients From UniQure (RTTNews)
24.06.20	uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy (GlobeNewswire)
19.06.20	uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease (GlobeNewswire)
17.06.20	uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors (GlobeNewswire)
15.06.20	uniQure Announces Change for its 2020 Annual General Meeting of Shareholders (GlobeNewswire)
14.05.20	uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting (GlobeNewswire)
29.04.20	uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
28.04.20	uniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting (GlobeNewswire)
17.04.20	uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors (GlobeNewswire)
30.03.20	uniQure to Participate in Multiple Upcoming Investor Conferences in April (GlobeNewswire)
02.03.20	uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters (GlobeNewswire)
27.02.20	uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference (GlobeNewswire)
04.02.20	uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	121.90	2.83 %	K V
Logitech Intl	72.20	1.66 %	K V
Swiss Re	129.85	1.21 %	K V
Lonza Grp	527.00	1.07 %	K V
UBS Group	28.42	0.42 %	K V
ABB	49.90	-0.52 %	K V
Swiss Life Hldg	728.20	-0.74 %	K V
Givaudan	3’903.00	-0.76 %	K V
Sonova Hldg	307.20	-1.57 %	K V
Novartis	92.11	-1.68 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Uniqure B.V.

Aktien Top/Flop

Meistgelesene Nachrichten